Anasuya Patel
Overview
Explore the profile of Anasuya Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mittal G, Jakhar P, Patel A, Bhagwat D
J Diabetes Metab Disord
. 2023 May;
22(1):385-392.
PMID: 37255782
Purpose: In diabetes, multi-organ level dysfunction arising from metabolic complications is reported to influence the pharmacokinetics (PK) profile of many drugs. Hence, the present study was planned in rats to...
2.
Nandanwar M, Kansagara A, Gupta S, Patel A, Patel M, Yeole R, et al.
J Appl Toxicol
. 2022 Feb;
42(8):1354-1370.
PMID: 35146781
Fluoroquinolone (FQ) antibacterials have drawn heightened attention from various international regulatory agencies due to their class-specific side effects. Levonadifloxacin is a novel broad spectrum benzoquinolizine FQ active against methicillin-resistant Staphyloccocus...
3.
Nandanwar M, Chavan R, Kansagara A, Patel M, Patel A, Yeole R, et al.
Regul Toxicol Pharmacol
. 2021 Feb;
122:104889.
PMID: 33587936
Ketolide antibiotics are known to cause hepatic injury. Nafithromycin, a novel lactone ketolide was therefore assessed for hepatic safety through range of preclinical in vitro (metabolic stability, CYP inhibition/induction assays)...
4.
Patel A, Sangle G, Trivedi J, Shengule S, Thorve D, Patil M, et al.
Antimicrob Agents Chemother
. 2020 Mar;
64(5).
PMID: 32152077
Fluoroquinolones are reported to possess immunomodulatory activity; hence, a novel benzoquinolizine fluoroquinolone, levonadifloxacin, was evaluated in lipopolysaccharide-stimulated human whole-blood (HWB) and mouse acute lung injury (ALI) models. Levonadifloxacin significantly mitigated...
5.
Trivedi J, Shaikh J, Chavan N, Thorve D, Chaudhary B, Karade A, et al.
Cytokine
. 2020 Mar;
129:155049.
PMID: 32126500
Acute respiratory distress syndrome following an acute lung injury (ALI) is a life threatening inflammatory condition predominantly characterized by vascular protein leakage, neutrophil recruitment and overexpression of proinflammatory cytokines. Pulmonary...
6.
Patel A, Khande H, Periasamy H, Mokale S
Inflammation
. 2020 Jan;
43(3):1035-1043.
PMID: 31955291
Acute lung injury is an inflammatory condition developed after severe sepsis in response to excessive secretion of pro-inflammatory cytokines. Doxycycline is widely reported to possess immunomodulatory activity through inhibition of...
7.
Iwanowski P, Bhatia A, Gupta M, Patel A, Chavan R, Yeole R, et al.
Antimicrob Agents Chemother
. 2019 Oct;
63(12).
PMID: 31591119
Nafithromycin (WCK 4873), a novel lactone-ketolide, was administered to healthy adult subjects in 2 randomized, double-blind, placebo-controlled, Phase 1 studies. In the first-in-human study, single-ascending oral doses of nafithromycin (100...
8.
Ahirrao V, Rane V, Patil K, Jadhav R, Patel A, Patil V, et al.
Biomed Chromatogr
. 2019 Apr;
33(9):e4566.
PMID: 31032954
A chiral liquid chromatographic method was developed and validated for the quantification of R-enantiomer impurity (RE) in WCK 3023 (S-enantiomer), a new drug substance. The separation was achieved on Chiralpak...
9.
Preston R, Mamikonyan G, DeGraff S, Chiou J, Kemper C, Xu A, et al.
Antimicrob Agents Chemother
. 2018 Nov;
63(1).
PMID: 30397067
WCK 5222 is a novel β-lactam-β-lactam-enhancer combination of cefepime (FEP) and zidebactam (ZID). ZID is a novel β-lactam enhancer with a dual action of binding to Gram-negative penicillin-binding protein 2...
10.
Mason J, Chugh R, Patel A, Gutte R, Bhatia A
Clin Transl Sci
. 2018 Oct;
12(1):47-52.
PMID: 30369076
The purpose of this study was to measure the electrocardiographic (ECG) effects of WCK 2349 (the L-alanine ester prodrug of levonadifloxacin) at a supratherapeutic oral dose of 2,600 mg. A...